Peregrine Pharmaceuticals CEO Nicholas Green's 2023 pay rises 5% to $6.5M
Peregrine Pharmaceuticals reports 2023 executive compensation
By ExecPay News
Published: August 28, 2023
Peregrine Pharmaceuticals reported fiscal year 2023 executive compensation information on August 28, 2023.
In 2023, five executives at Peregrine Pharmaceuticals received on average a compensation package of $2.4M, a 23% decrease compared to previous year.
Average pay of disclosed executives at Peregrine Pharmaceuticals
Nicholas S. Green, Chief Executive Officer, received $6.5M in total, which increased by 5% compared to 2022. 79% of Green's compensation, or $5.1M, was in stock awards. Green also received $662K in non-equity incentive plan, $642K in salary, as well as $45K in other compensation.
For fiscal year 2023, the median employee pay was $104,595 at Peregrine Pharmaceuticals. Therefore, the ratio of Nicholas S. Green's pay to the median employee pay was 62 to one.
Daniel R. Hart, Chief Financial Officer, received a compensation package of $1.9M, which decreased by 6% compared to previous year. 63% of the compensation package, or $1.2M, was in stock awards.
Mark R. Ziebell, General Counsel, earned $1.4M in 2023, a 7% increase compared to previous year.
Matthew R. Kwietniak, Chief Commercial Officer, received $1.3M in 2023.
Richard A. Richieri, Chief Operations Officer, earned $1.1M in 2023.
Peregrine Pharmaceuticals' fiscal year ends on April 30.
Related executives
Nicholas Green
Peregrine Pharmaceuticals
Chief Executive Officer
Daniel Hart
Peregrine Pharmaceuticals
Chief Financial Officer
Richard Richieri
Peregrine Pharmaceuticals
Chief Operations Officer
Matthew Kwietniak
Peregrine Pharmaceuticals
Chief Commercial Officer
Mark Ziebell
Peregrine Pharmaceuticals
General Counsel
You may also like
Source: SEC filing on August 28, 2023.